Search
for
Sort by
Research 751–780 of 1000+
- British Association of Dermatologists living guideline for managing people with alopecia areata 2024
- Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning
- Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
- Premature hair graying: a multifaceted phenomenon
- Evaluating Scarring Alopecia Therapies from the Patient Perspective: Knowledge, Barriers to Care, and Treatment Satisfaction
- Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report
- Drug Repurposing Patent Applications April–June 2021
- Chaperones as thermodynamic sensors
- Enzymes
- Alopecia areata: recognition, diagnosis and management
- Regulation of self-renewal in colorectal cancer cell models
- Alopecia universalis following human papillomavirus vaccine administration: a case report
- Costunolide—A Bioactive Sesquiterpene Lactone with Diverse Therapeutic Potential
- Localizing the ROS Signal
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
- Computational Evaluation of Dibenzo Compounds as Potential Dual Inhibitors of Androgen Receptor and 5α-Reductase
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Case Report: Multimodal contact immunotherapy in alopecia areata: long-term clinical experience in the JAK inhibitor era
- Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK/STAT inhibitors?
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Biologic Therapies and Small-Molecule Inhibitors for Dissecting Cellulitis of the Scalp: A Systematic Review
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Identifying novel strategies for treating human hair loss disorders: Cyclosporine A suppresses the Wnt inhibitor, SFRP1, in the dermal papilla of human scalp hair follicles